Hepatitis C Virus NS5A Inhibitor [EPC]

43367 reported adverse events

Drugs of this class: LEDIPASVIR AND SOFOSBUVIR VELPATASVIR AND SOFOSBUVIR ELBASVIR AND GRAZOPREVIR GLECAPREVIR AND PIBRENTASVIR SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR

These side effects are most commonly reported by patients taking drugs of the Hepatitis C Virus NS5A Inhibitor [EPC] class:

#	Side effect	Count
0	FATIGUE	10031
1	HEADACHE	8643
2	NAUSEA	3827
3	DIARRHOEA	2230
4	INSOMNIA	1705
5	DRUG INEFFECTIVE	1665
6	HEPATITIS C	1329
7	PRURITUS	1121
8	VOMITING	1102
9	DRUG DOSE OMISSION	1039

See all common reactions for Hepatitis C Virus NS5A Inhibitor [EPC]

Drugs of the Hepatitis C Virus NS5A Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	HEPATITIS C VIRUS TEST POSITIVE	160	0.3245
1	VIRAL LOAD UNDETECTABLE	12	0.2308
2	HEPATIC CANCER RECURRENT	46	0.2091
3	GENOTYPE DRUG RESISTANCE TEST POSITIVE	186	0.2062
4	HEPATITIS C RNA	7	0.1944
5	HEPATITIS C RNA POSITIVE	29	0.1847
6	HEPATITIS C	1329	0.1225
7	VIRAL LOAD	14	0.1053
8	VIRAL LOAD DECREASED	12	0.0952
9	HEPATOCELLULAR CARCINOMA	515	0.0888

See all enriched reactions for Hepatitis C Virus NS5A Inhibitor [EPC]